Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
17 NC counties are under alert, including Northampton County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
78.67
+0.76 (+0.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4,635,090
Open
77.97
Bid (Size)
77.50 (2)
Ask (Size)
79.00 (1)
Prev. Close
77.91
Today's Range
77.73 - 78.80
52wk Range
60.47 - 87.67
Shares Outstanding
N/A
Dividend Yield
1.18%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Today 14:51 EDT
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
Today 9:30 EDT
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
Via
News Direct
Performance
YTD
+15.01%
+15.01%
1 Month
-8.22%
-8.22%
3 Month
+0.94%
+0.94%
6 Month
+16.98%
+16.98%
1 Year
+17.89%
+17.89%
More News
Read More
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
Today 7:00 EDT
From
AstraZeneca
Via
Business Wire
Is Summit Therapeutics Stock a Buy?
September 30, 2024
Via
The Motley Fool
Week In Review: Zenas Raises $259 Million In IPO
September 28, 2024
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Top Stock Reports For Toyota, AstraZeneca & Chubb
September 26, 2024
Via
Talk Markets
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
September 26, 2024
Via
Benzinga
Exposures
Product Safety
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
September 26, 2024
From
AstraZeneca
Via
Business Wire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
September 26, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
September 23, 2024
Via
Benzinga
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
September 23, 2024
Via
Investor's Business Daily
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
September 23, 2024
Via
Benzinga
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
September 23, 2024
From
AstraZeneca
Via
Business Wire
FLUMIST approved for self-administration in the US
September 20, 2024
From
AstraZeneca
Via
Business Wire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
September 19, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
Via
Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
September 18, 2024
Via
Benzinga
Exposures
Product Safety
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
September 18, 2024
From
AstraZeneca
Via
Business Wire
5 Oversold Stocks to Buy Right Now
September 16, 2024
Via
MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
September 17, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
September 16, 2024
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
September 15, 2024
From
AstraZeneca
Via
Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
September 13, 2024
From
AstraZeneca
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.